{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:54:50Z","timestamp":1781848490267,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Multidrug-resistant\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (MDRAB) pneumonia is a major cause of mortality in hospital-acquired infections due to extensive drug resistance and limited therapeutic options. Optimizing treatment and identifying mortality-related factors are urgently needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy of different antibacterial regimens in MDRAB pneumonia and determine independent risk factors for 28-day all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study included 142 MDRAB pneumonia patients from February 2022 to February 2025. Patients were divided into three groups: Group A, sulbactam-containing combinations (n = 63); Group B, polymyxins + tigecycline (n = 45); Group C, other regimens (n = 34). Outcomes included bacterial resistance patterns, 28-day mortality, dynamic PCT and CRP levels, APACHE II and SOFA scores, and lymphocyte subsets. Multivariate logistic regression identified mortality predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Group A showed the lowest resistance to cefoperazone\/sulbactam (30.16%) and the highest sensitivity (71.43%, both P&amp;lt; 0.05). Group B had the highest tigecycline resistance (31.11%). The 28-day mortality rates were 39.68% (A), 60.00% (B), and 64.71% (C) (P\u00a0=\u00a00.028). Independent mortality predictors were APACHE II, SOFA, and CD4+\/CD8+ ratio (all P&amp;lt; 0.01). On day 7, Group A had the lowest PCT, while Group C showed the smallest declines in PCT and CRP. Group A exhibited the highest CD4+\/CD8+ ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sulbactam-based combination therapy was associated with improved pathogen clearance and survival in this retrospective cohort. Mortality is closely linked to initial disease severity and early organ dysfunction. Dynamic changes in PCT and CD4+\/CD8+ ratio have significant prognostic value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1819679","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:44Z","timestamp":1781848064000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia"],"prefix":"10.3389","volume":"16","author":[{"given":"Meng","family":"Xu","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Affiliated Hospital of Qinghai University","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care, Jiading Branch of Shanghai General Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Tongren People\u2019s Hospital","place":["Tongren, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Shanghai Fourth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1469-0691.2007.01847.x","article-title":"Sulbactam-containing beta-lactamase inhibitor combinations","volume":"14","author":"Akova","year":"2008","journal-title":"Clin. Microbiol. Infection: Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11040487","article-title":"The impact of multidrug-resistant acinetobacter baumannii infection in critically ill patients with or without COVID-19 infection","volume":"11","author":"Alenazi","year":"2023","journal-title":"Health Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081086","article-title":"Acinetobacter baumannii infection-related mortality in hospitalized patients: risk factors and potential targets for clinical and antimicrobial stewardship interventions","volume":"11","author":"Alrahmany","year":"2022","journal-title":"Antibiotics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1060736","article-title":"Biochemical exploration of \u03b2-lactamase inhibitors","volume":"13","author":"Arer","year":"2023","journal-title":"Front. Genet."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030119","article-title":"Insights into acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen","volume":"9","author":"Ayoub Moubareck","year":"2020","journal-title":"Antibiotics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10096-025-05080.1","article-title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers","volume":"44","author":"Boattini","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global epidemiology and mechanisms of resistance of acinetobacter baumannii-calcoaceticus complex","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin. Infect. Diseases: An. Off. Publ. Infect. Dis. Soc. America"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/Tropicalmed10010015","article-title":"Multidrug-resistant acinetobacter baumannii: risk factors for mortality in a tertiary care teaching hospital","volume":"10","author":"\u010cerniauskien\u0117","year":"2025","journal-title":"Trop. Med. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12879-018-3511-0","article-title":"Molecular characterization of multidrug resistant strains of acinetobacter baumannii isolated from pediatric intensive care unit in a chinese tertiary hospital","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/ccm.0000000000000933","article-title":"Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant acinetobacter baumannii bacteremia: a multicenter prospective observational study","volume":"43","author":"Cheng","year":"2015","journal-title":"Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02207-23","article-title":"Nosocomial surveillance of multidrug-resistant acinetobacter baumannii: a genomic epidemiological study","volume":"12","author":"Duan","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/qco.0000000000001001","article-title":"Current treatment options for pneumonia caused by carbapenem-resistant acinetobacter baumannii","volume":"37","author":"Franzone","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13111001","article-title":"Monitoring immune dysfunction in critically ill patients with carbapenem-resistant acinetobacter baumannii sepsis treated with regimens including cefiderocol: a pilot study to identify accessible biomarkers to stratify patients\u2019 prognosis","volume":"13","author":"Frattari","year":"2024","journal-title":"Antibiotics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: a stewardship program\u2019s evaluation of minocycline for multidrug-resistant acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin. Infect. Diseases: An. Off. Publ. Infect. Dis. Soc. America"},{"key":"B16","volume-title":"Statistical methods for meta-analysis","author":"Hedges","year":"1985"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/jac\/dkad042","article-title":"Early initiation of three-drug combinations for the treatment of carbapenem-resistant a. baumannii among COVID-19 patients","volume":"78","author":"Heil","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13090907","article-title":"Comparing the outcomes of cefoperazone\/sulbactam-based and non-cefoperazone\/sulbactam-based therapeutic regimens in patients with multiresistant acinetobacter baumannii infections\u2014a meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Antibiotics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","article-title":"Multidrug-resistant acinetobacter baumannii as an emerging concern in hospitals","volume":"48","author":"Ibrahim","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40560-015-0077-4","article-title":"Prognostic factors associated with mortality of drug-resistant acinetobacter baumannii ventilator-associated pneumonia","volume":"3","author":"Inchai","year":"2015","journal-title":"J. Intensive Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071200","article-title":"Moving toward extensively drug-resistant: four-year antimicrobial resistance trends of acinetobacter baumannii from the largest department of internal medicine in Slovakia","volume":"12","author":"Jalali","year":"2023","journal-title":"Antibiotics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/idr.s305819","article-title":"Outcomes of adjunctive therapy with intravenous cefoperazone-sulbactam for ventilator-associated pneumonia due to carbapenem-resistant acinetobacter baumannii","volume":"14","author":"Kanchanasuwan","year":"2021","journal-title":"Infection Drug Resistance"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10111344","article-title":"Systematic review of antimicrobial combination options for pandrug-resistant acinetobacter baumannii","volume":"10","author":"Karakonstantis","year":"2021","journal-title":"Antibiotics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and a. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/s1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by acinetobacter baumannii-calcoaceticus complex: a multicenter, randomized, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12879-024-09335-8","article-title":"Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with acinetobacter baumannii bacteremia","volume":"24","author":"Lan","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1093\/ofid\/ofu052.204","article-title":"338: prevalence, mortality and outcomes of antibiotic therapy of multi-drug resistant acinetobacter baumannii","volume":"1","author":"Lapensee","year":"2014","journal-title":"Open Forum Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12325-023-02436-x","article-title":"Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: a review of pathophysiological mechanism and treatment options","volume":"40","author":"Le","year":"2023","journal-title":"Adv. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.2147\/idr.s491858","article-title":"Molecular epidemiology and genetic characterization of carbapenem-resistant acinetobacter baumannii isolates from the ICU of a tertiary hospital in east China","volume":"17","author":"Liu","year":"2024","journal-title":"Infection Drug Resistance"},{"key":"B30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12931-024-02779-1","article-title":"Multidrug-resistant pathogens and ventilator-associated pneumonia in critically ill COVID-19 and non-COVID-19 patients: a prospective observational monocentric comparative study","volume":"25","author":"Montrucchio","year":"2024","journal-title":"Respir. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/jam.15130","article-title":"Carbapenem resistance in acinetobacter baumannii, and their importance in hospital\u2010acquired infections: a scientific review","volume":"131","author":"Nguyen","year":"2025"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2025"},{"key":"B33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13756-019-0502-x","article-title":"Comparison of tigecycline or cefoperazone\/sulbactam therapy for bloodstream infection due to carbapenem-resistant acinetobacter baumannii","volume":"8","author":"Niu","year":"2019","journal-title":"Antimicrobial Resistance Infection Control"},{"key":"B34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3947\/ic.2024.0038","article-title":"Guidelines for antibacterial treatment of carbapenem-resistant enterobacterales infections","volume":"56","author":"Park","year":"2024","journal-title":"Infection Chemotherapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5414\/cp203102","article-title":"Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant acinetobacter baumannii","volume":"56","author":"Qin","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.541423","article-title":"Synergistic antibacterial activity of combined antimicrobials and the clinical outcome of patients with carbapenemase-producing acinetobacter baumannii infection","volume":"11","author":"Qu","year":"2020","journal-title":"Front. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf055","article-title":"Sulbactam for carbapenem-resistant acinetobacter baumannii infections: a literature review","author":"Spernovasilis","year":"2025"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107267","article-title":"Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant acinetobacter baumannii pneumonia: a randomized controlled trial","volume":"149","author":"Ungthammakhun","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10096-024-04831-w","article-title":"In vitro activity of cefiderocol against carbapenem-resistant acinetobacter baumannii carrying various \u03b2-lactamase encoding genes","volume":"43","author":"Uskudar-Guclu","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1562537","article-title":"Immunosenescence markers in T- and NK-cells according to the CD4\/CD8 ratio in successfully treated people living with HIV","volume":"12","author":"Vassallo","year":"2025","journal-title":"Front. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40121-017-0149-y","article-title":"Anticipating the unpredictable: a review of antimicrobial stewardship and acinetobacter infections","volume":"6","author":"Wenzler","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ajic.2022.08.004","article-title":"Comparison of pneumonia and nonpneumonia-related acinetobacter baumannii complex bacteremia: a single-center retrospective study","volume":"51","author":"Xu","year":"2023","journal-title":"Am. J. Infection Control"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1565965","article-title":"The intricacies of acinetobacter baumannii: a multifaceted comprehensive review of a multidrug-resistant pathogen and its clinical significance and implications","volume":"16","author":"Yehya","year":"2025","journal-title":"Front. Microbiol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020273","article-title":"Intravenous polymyxin B as adjunctive therapy to high-dose tigecycline for the treatment of nosocomial pneumonia due to carbapenem-resistant acinetobacter baumannii and klebsiella pneumoniae: a propensity score-matched cohort study","volume":"12","author":"Zha","year":"2023","journal-title":"Antibiotics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000014937","article-title":"Risk factors for acquisition and mortality of multidrug-resistant acinetobacter baumannii bacteremia: a retrospective study from a chinese hospital","volume":"98","author":"Zhou","year":"2019","journal-title":"Medicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1217270","article-title":"Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against acinetobacter baumannii","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1819679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:45Z","timestamp":1781848065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1819679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":46,"alternative-id":["10.3389\/fcimb.2026.1819679"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1819679","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1819679"}}